Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
-
Published:2024-02
Issue:
Volume:188
Page:107468
-
ISSN:0169-5002
-
Container-title:Lung Cancer
-
language:en
-
Short-container-title:Lung Cancer
Author:
Zhao ShenORCID, Ma Yuxiang, Liu Lianke, Fang Jian, Ma Haiqing, Feng Guosheng, Xie Bo, Zeng Shan, Chang Jianhua, Ren Jun, Zhang Yingjun, Xi Ning, Zhuang Yulei, Jiang Yingzhi, Zhang Qi, Kang Ning, Zhang Li, Zhao HongyunORCID
Reference33 articles.
1. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer;Castellanos;J. Thoracic Oncol.,2017 2. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management;Cooper;Nat Rev Clin Oncol,2022 3. Le, X. et al. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research 24, 6195-6203, doi:10.1158/1078-0432.Ccr-18-1542 (2018). 4. Hartmaier, R. J. et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer discovery 13, 98-113, doi:10.1158/2159-8290.CD-22-0586 (2023). 5. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial;Wu;Lancet Respir Med,2020
|
|